Cervical Cancer disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

CERCA MCID: CRV035 MIFTS: 76	Cervical Cancer (CERCA) Categories: Cancer diseases, Genetic diseases, Reproductive diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs Expand all tables

Sources

Aliases & Classifications for Cervical Cancer

MalaCards integrated aliases for Cervical Cancer:

Name: Cervical Cancer ⁵⁸ ³⁹ ¹² ⁷⁷ ⁷⁶ ³⁸ ⁵⁶ ⁴⁴ ³ ¹⁵ ⁶⁴ ⁷⁴

Uterine Cervical Neoplasms ⁶ ⁴⁵

Uterine Cervical Neoplasm ¹² ⁷⁴

Cervical Cancer, Somatic ⁵⁸ ¹³

Cervix Cancer ¹² ⁷⁶

Neoplasm of Uterine Cervix ¹²

Tumor of the Cervix Uteri ¹²

Cancer, Cervical, Somatic ⁴¹

Malignant Tumor of Cervix ⁷⁴

Uterine Cervical Cancer ⁷⁶

Cervix Uteri Cancer ¹²

Neoplasms Cervical ⁵⁶

Cervical Neoplasm ¹²

Cervix Carcinoma ⁷⁴

Cerca ⁷⁶

Characteristics:

HPO:

³³

cervical cancer:
Inheritance somatic mutation

Classifications:

MalaCards categories:
Global: Genetic diseases Cancer diseases
Anatomical: Reproductive diseases

See all MalaCards categories (disease lists)

ICD10: ³⁴

Neoplasms

Malignant neoplasms of female genital organs

Malignant neoplasm of cervix uteri

Malignant neoplasm: Cervix uteri, unspecified

External Ids:

Disease Ontology ¹² DOID:4362

OMIM ⁵⁸ 603956

KEGG ³⁸ H00030

ICD9CM ³⁶ 180 180.9

MeSH ⁴⁵ D002583

NCIt ⁵¹ C2940 C9311

SNOMED-CT ⁶⁹ 93752005

ICD10 ³⁴ C53 C53.9

MedGen ⁴³ C0302592 C4048328

SNOMED-CT via HPO ⁷⁰ 108369006 124975008 363346000

UMLS ⁷⁴ C0007847 C0007873 C0302592 more

Sources

Summaries for Cervical Cancer

MedlinePlus : ⁴⁴ The cervix is the lower part of the uterus, the place where a baby grows during pregnancy. Cervical cancer is caused by a virus called HPV. The virus spreads through sexual contact. Most women's bodies are able to fight HPV infection. But sometimes the virus leads to cancer. You're at higher risk if you smoke, have had many children, use birth control pills for a long time, or have HIV infection. Cervical cancer may not cause any symptoms at first. Later, you may have pelvic pain or bleeding from the vagina. It usually takes several years for normal cells in the cervix to turn into cancer cells. Your health care provider can find abnormal cells by doing a Pap test to examine cells from the cervix. You may also have an HPV test. If your results are abnormal, you may need a biopsy or other tests. By getting regular screenings, you can find and treat any problems before they turn into cancer. Treatment may include surgery, radiation therapy, chemotherapy, or a combination. The choice of treatment depends on the size of the tumor, whether the cancer has spread and whether you would like to become pregnant someday. Vaccines can protect against several types of HPV, including some that can cause cancer. NIH: National Cancer Institute

MalaCards based summary : Cervical Cancer, also known as uterine cervical neoplasms, is related to cervix carcinoma and cervix disease, and has symptoms including pelvic pain An important gene associated with Cervical Cancer is FGFR3 (Fibroblast Growth Factor Receptor 3), and among its related pathways/superpathways are Human papillomavirus infection and Viral carcinogenesis. The drugs Cervarix and Gardasil have been mentioned in the context of this disorder. Affiliated tissues include cervix, testes and lymph node, and related phenotypes are neoplasm and abnormality of the cervical spine

Disease Ontology : ¹² A female reproductive organ cancer that is located in the cervix.

CDC : ³ Early on, cervical cancer may not cause signs and symptoms. Advanced cervical cancer may cause bleeding or discharge from the vagina that is not normal for you, such as bleeding after sex. If you have any of these signs, see your doctor. They may be caused by something other than cancer, but the only way to know is to see your doctor.

UniProtKB/Swiss-Prot : ⁷⁶ Cervical cancer: A malignant neoplasm of the cervix, typically originating from a dysplastic or premalignant lesion previously present at the active squamocolumnar junction. The transformation from mild dysplastic to invasive carcinoma generally occurs slowly within several years, although the rate of this process varies widely. Carcinoma in situ is particularly known to precede invasive cervical cancer in most cases. Cervical cancer is strongly associated with infection by oncogenic types of human papillomavirus.

PubMed Health : ⁶⁴ About cervical cancer: Cervical cancer is the term used to describe tumors that can grow at the lower end of the womb. These tumors usually develop from abnormal cell changes at the entrance to the womb from the vagina (the opening of the cervix). Abnormal cell changes can be detected through screening and then removed. A vaccine against viruses that cause cancer (HPV vaccine) can reduce the risk of cervical cancer.The cervix (neck of the womb) is a strong, muscular tube-like structure. The very bottom end of the cervix sticks out into the vagina a little, at the opening of the cervix. The inside of the cervix is lined with a mucous membrane. Glands in the mucous membrane produce a thick liquid (cervical mucus) that acts as a barrier, preventing germs from entering the womb from the vagina.

Wikipedia : ⁷⁷ Cervical cancer is a cancer arising from the cervix. It is due to the abnormal growth of cells that have... more...

Description from OMIM: 603956

Sources

Related Diseases for Cervical Cancer

Diseases related to Cervical Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 452)

#	Related Disease	Score	Top Affiliating Genes
1	cervix carcinoma	33.1	FGFR3 STAT3 TP53
2	cervix disease	32.7	AKT1 CCND1 CTNNB1 TP53
3	papilloma	32.1	CCND1 FGFR3 PTEN TP53
4	squamous cell carcinoma	31.9	AKT1 CCND1 CTNNB1 ERBB2 FGFR3 HOTAIR
5	adenocarcinoma	31.4	AKT1 CCND1 CTNNB1 ERBB2 FGFR3 GNAS
6	breast cancer	31.4	AKT1 CCND1 CTNNB1 ERBB2 GNAS HOTAIR
7	endometrial cancer	31.3	AKT1 CCND1 CTNNB1 ERBB2 HOTAIR HRAS
8	ovarian cancer	31.2	AKT1 CCND1 CTNNB1 ERBB2 HOTAIR MIR21
9	sarcoma	31.2	CTNNB1 HOTAIR HRAS MTOR PIK3CA TP53
10	lung cancer	31.0	AKT1 CCND1 ERBB2 FGFR3 HOTAIR HRAS
11	kaposi sarcoma	30.9	AKT1 MTOR STAT3 TP53
12	prostate cancer	30.9	AKT1 CCND1 CTNNB1 ERBB2 HOTAIR HRAS
13	gastric cancer	30.8	AKT1 CCND1 CTNNB1 ERBB2 HOTAIR MIR21
14	colorectal cancer	30.8	AKT1 CCND1 CTNNB1 ERBB2 FGFR3 GNAS
15	ovarian cancer 1	30.7	AKT1 ERBB2 PIK3CA TP53
16	hepatocellular carcinoma	30.7	AKT1 CCEPR CCND1 CTNNB1 GNAS HOTAIR
17	lung cancer susceptibility 3	30.7	AKT1 CCND1 CTNNB1 ERBB2 FGFR3 GNAS
18	small cell cancer of the lung	30.7	AKT1 HOTAIR MIR21 PIK3CA PTEN TP53
19	colorectal adenoma	30.6	CTNNB1 HRAS TP53
20	adenoma	30.6	CCND1 CTNNB1 GNAS SMAD4 TP53
21	esophageal cancer	30.6	AKT1 CCND1 CTNNB1 ERBB2 HOTAIR HRAS
22	carcinosarcoma	30.6	CTNNB1 ERBB2 HRAS PIK3CA PTEN TP53
23	uterine carcinosarcoma	30.6	CTNNB1 ERBB2 HRAS PIK3CA PTEN TP53
24	tongue squamous cell carcinoma	30.5	AKT1 CTNNB1 MIR21 TP53
25	peutz-jeghers syndrome	30.5	CTNNB1 PTEN SMAD4 TP53
26	penile cancer	30.5	CCND1 PIK3CA TP53
27	bladder cancer	30.5	CCEPR CCND1 ERBB2 FGFR3 HOTAIR HRAS
28	osteogenic sarcoma	30.5	AKT1 HOTAIR PVT1 TP53
29	pancreas adenocarcinoma	30.5	AKT1 CCND1 CTNNB1 ERBB2 GNAS HRAS
30	oral cancer	30.4	CCND1 MIR21 TP53
31	primitive neuroectodermal tumor of the cervix uteri	12.6
32	malignant germ cell tumor of the cervix uteri	12.5
33	cervical intraepithelial neoplasia	11.5
34	carcinosarcoma of the cervix uteri	11.4
35	radiation proctitis	11.3
36	cervical carcinosarcoma	11.0
37	cervix melanoma	11.0
38	cervix endometrial stromal tumor	11.0
39	diethylstilbestrol syndrome	11.0
40	glioblastoma multiforme	10.9	AKT1 CCND1 ERBB2 MIR21 MTOR PIK3CA
41	medulloblastoma	10.9	AKT1 CCND1 CTNNB1 ERBB2 HOTAIR PIK3CA
42	glioblastoma	10.8	AKT1 CCND1 ERBB2 HOTAIR HRAS MIR21
43	uterine anomalies	10.8	AKT1 CCND1 CTNNB1 ERBB2 PIK3CA PTEN
44	cholangiocarcinoma	10.8	AKT1 CCND1 CTNNB1 ERBB2 MIR21 MTOR
45	estrogen-receptor positive breast cancer	10.8	AKT1 CCND1 ERBB2 MTOR PIK3CA TP53
46	respiratory system cancer	10.8	AKT1 CCND1 CTNNB1 ERBB2 HRAS PIK3CA
47	bladder disease	10.8	AKT1 CCND1 ERBB2 FGFR3 TP53
48	glioma	10.8	CCND1 ERBB2 HOTAIR MIR21 PIK3CA PTEN
49	adenoid cystic carcinoma	10.8	AKT1 CCND1 CTNNB1 ERBB2 HRAS PIK3CA
50	adamantinoma of long bones	10.8	CCND1 CTNNB1 ERBB2 HOTAIR PIK3CA PTEN

Comorbidity relations with Cervical Cancer via Phenotypic Disease Network (PDN):

Acute Cystitis	Deficiency Anemia
Hydronephrosis	Intestinal Obstruction
Vaginal Cancer

Graphical network of the top 20 diseases related to Cervical Cancer:

Sources

Symptoms & Phenotypes for Cervical Cancer

Human phenotypes related to Cervical Cancer:

³³

#	Description	HPO Frequency	HPO Source Accession
1	neoplasm ³³		HP:0002664
2	abnormality of the cervical spine ³³		HP:0003319

Clinical features from OMIM:

603956

UMLS symptoms related to Cervical Cancer:

pelvic pain

GenomeRNAi Phenotypes related to Cervical Cancer according to GeneCards Suite gene sharing:

²⁷ (show top 50) (show all 57)

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	Increased shRNA abundance (Z-score > 2)	GR00366-A-105	10.56	MTOR
2	Increased shRNA abundance (Z-score > 2)	GR00366-A-107	10.56	SMAD4
3	Increased shRNA abundance (Z-score > 2)	GR00366-A-11	10.56	MTOR SMAD4
4	Increased shRNA abundance (Z-score > 2)	GR00366-A-116	10.56	PIK3CA
5	Increased shRNA abundance (Z-score > 2)	GR00366-A-126	10.56	CCND1
6	Increased shRNA abundance (Z-score > 2)	GR00366-A-151	10.56	PTEN
7	Increased shRNA abundance (Z-score > 2)	GR00366-A-152	10.56	PTEN CCND1
8	Increased shRNA abundance (Z-score > 2)	GR00366-A-157	10.56	PIK3CA
9	Increased shRNA abundance (Z-score > 2)	GR00366-A-16	10.56	AKT1 MTOR PIK3CA PTEN CCND1
10	Increased shRNA abundance (Z-score > 2)	GR00366-A-163	10.56	CCND1
11	Increased shRNA abundance (Z-score > 2)	GR00366-A-166	10.56	PIK3CA
12	Increased shRNA abundance (Z-score > 2)	GR00366-A-168	10.56	PTEN
13	Increased shRNA abundance (Z-score > 2)	GR00366-A-177	10.56	AKT1 PIK3CA CCND1
14	Increased shRNA abundance (Z-score > 2)	GR00366-A-190	10.56	PIK3CA
15	Increased shRNA abundance (Z-score > 2)	GR00366-A-195	10.56	SMAD4
16	Increased shRNA abundance (Z-score > 2)	GR00366-A-199	10.56	CCND1
17	Increased shRNA abundance (Z-score > 2)	GR00366-A-21	10.56	SMAD4 CCND1
18	Increased shRNA abundance (Z-score > 2)	GR00366-A-210	10.56	CCND1
19	Increased shRNA abundance (Z-score > 2)	GR00366-A-214	10.56	PTEN
20	Increased shRNA abundance (Z-score > 2)	GR00366-A-25	10.56	SMAD4 CCND1
21	Increased shRNA abundance (Z-score > 2)	GR00366-A-36	10.56	CCND1
22	Increased shRNA abundance (Z-score > 2)	GR00366-A-42	10.56	AKT1 MTOR PIK3CA PTEN SMAD4
23	Increased shRNA abundance (Z-score > 2)	GR00366-A-43	10.56	SMAD4
24	Increased shRNA abundance (Z-score > 2)	GR00366-A-46	10.56	SMAD4
25	Increased shRNA abundance (Z-score > 2)	GR00366-A-49	10.56	PIK3CA
26	Increased shRNA abundance (Z-score > 2)	GR00366-A-50	10.56	AKT1
27	Increased shRNA abundance (Z-score > 2)	GR00366-A-54	10.56	SMAD4
28	Increased shRNA abundance (Z-score > 2)	GR00366-A-63	10.56	PTEN
29	Increased shRNA abundance (Z-score > 2)	GR00366-A-70	10.56	AKT1
30	Increased shRNA abundance (Z-score > 2)	GR00366-A-73	10.56	MTOR SMAD4
31	Increased shRNA abundance (Z-score > 2)	GR00366-A-74	10.56	SMAD4
32	Increased shRNA abundance (Z-score > 2)	GR00366-A-79	10.56	AKT1
33	Increased shRNA abundance (Z-score > 2)	GR00366-A-81	10.56	SMAD4
34	Increased shRNA abundance (Z-score > 2)	GR00366-A-85	10.56	AKT1 MTOR
35	Increased shRNA abundance (Z-score > 2)	GR00366-A-93	10.56	PTEN
36	Decreased viability	GR00055-A-2	10.35	HRAS MTOR PIK3CA
37	Decreased viability	GR00221-A-1	10.35	AKT1 FGFR3 HRAS MTOR PIK3CA
38	Decreased viability	GR00221-A-2	10.35	AKT1 FGFR3 HRAS PIK3CA
39	Decreased viability	GR00221-A-3	10.35	AKT1 FGFR3 HRAS
40	Decreased viability	GR00221-A-4	10.35	AKT1 MTOR PIK3CA
41	Decreased viability	GR00342-S-1	10.35	MTOR
42	Decreased viability	GR00342-S-2	10.35	MTOR
43	Decreased viability	GR00402-S-2	10.35	AKT1 FGFR3 HRAS MTOR PIK3CA
44	Decreased shRNA abundance (Z-score < -2)	GR00366-A-10	10.17	FGFR3
45	Decreased shRNA abundance (Z-score < -2)	GR00366-A-148	10.17	ERBB2
46	Decreased shRNA abundance (Z-score < -2)	GR00366-A-173	10.17	MTOR
47	Decreased shRNA abundance (Z-score < -2)	GR00366-A-213	10.17	AKT1
48	Decreased shRNA abundance (Z-score < -2)	GR00366-A-216	10.17	PIK3CA
49	Decreased shRNA abundance (Z-score < -2)	GR00366-A-53	10.17	MTOR PIK3CA
50	Decreased shRNA abundance (Z-score < -2)	GR00366-A-59	10.17	FGFR3

MGI Mouse Phenotypes related to Cervical Cancer:

⁴⁷ (show all 25)

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	behavior/neurological	MP:0005386	10.46	AKT1 CCND1 CTNNB1 ERBB2 FGFR3 GNAS
2	cardiovascular system	MP:0005385	10.42	AKT1 CCND1 CTNNB1 ERBB2 GNAS HRAS
3	cellular	MP:0005384	10.42	AKT1 CCND1 CTNNB1 ERBB2 FGFR3 GNAS
4	growth/size/body region	MP:0005378	10.41	AKT1 CCND1 CTNNB1 ERBB2 FGFR3 GNAS
5	homeostasis/metabolism	MP:0005376	10.39	AKT1 CCND1 CTNNB1 ERBB2 FGFR3 GNAS
6	endocrine/exocrine gland	MP:0005379	10.35	AKT1 CCND1 CTNNB1 ERBB2 GNAS HRAS
7	integument	MP:0010771	10.34	AKT1 CCND1 CTNNB1 ERBB2 FGFR3 GNAS
8	mortality/aging	MP:0010768	10.32	AKT1 CCND1 CTNNB1 ERBB2 FGFR3 GNAS
9	immune system	MP:0005387	10.31	AKT1 CCND1 CTNNB1 FGFR3 GNAS MTOR
10	craniofacial	MP:0005382	10.3	CCND1 CTNNB1 ERBB2 FGFR3 GNAS HRAS
11	hematopoietic system	MP:0005397	10.3	AKT1 CCND1 CTNNB1 FGFR3 GNAS MTOR
12	digestive/alimentary	MP:0005381	10.29	CCND1 CTNNB1 ERBB2 FGFR3 HRAS NFE2L2
13	embryo	MP:0005380	10.28	AKT1 CTNNB1 ERBB2 MTOR NFE2L2 PIK3CA
14	neoplasm	MP:0002006	10.25	AKT1 CCND1 CTNNB1 ERBB2 FGFR3 GNAS
15	nervous system	MP:0003631	10.25	AKT1 CCND1 CTNNB1 ERBB2 FGFR3 GNAS
16	adipose tissue	MP:0005375	10.22	AKT1 GNAS MTOR NFE2L2 PIK3CA PTEN
17	muscle	MP:0005369	10.16	AKT1 CTNNB1 ERBB2 GNAS MTOR PIK3CA
18	normal	MP:0002873	10.13	AKT1 CCND1 CTNNB1 ERBB2 FGFR3 GNAS
19	liver/biliary system	MP:0005370	10.1	AKT1 CTNNB1 GNAS NFE2L2 PTEN SMAD4
20	limbs/digits/tail	MP:0005371	10.05	CTNNB1 ERBB2 FGFR3 GNAS PTEN SMAD4
21	renal/urinary system	MP:0005367	9.96	CTNNB1 FGFR3 GNAS HRAS MTOR NFE2L2
22	no phenotypic analysis	MP:0003012	9.91	CTNNB1 FGFR3 GNAS HRAS MTOR PIK3CA
23	reproductive system	MP:0005389	9.85	AKT1 CCND1 CTNNB1 ERBB2 FGFR3 PIK3CA
24	respiratory system	MP:0005388	9.73	AKT1 CCND1 CTNNB1 ERBB2 FGFR3 GNAS
25	skeleton	MP:0005390	9.47	AKT1 CCND1 CTNNB1 ERBB2 FGFR3 GNAS

Sources

Drugs & Therapeutics for Cervical Cancer

PubMedHealth treatment related to Cervical Cancer: ⁶⁴

The most appropriate type of treatment will mainly depend on the size of the tumor and whether the cancer has spread. If the tumor is discovered at a very early stage, a small surgical procedure (conization) might be enough. If the tumor has already spread to the surrounding tissue, doctors usually recommend having surgery to remove the entire womb (a hysterectomy). The lymph nodes are removed in a wide area around the womb too. Radiotherapy might also be considered. Radiotherapy is still an option even if the tumor can no longer be removed through surgery. In some patients it can be combined with chemotherapy.

FDA approved drugs:

#	Drug Name	Active Ingredient(s) ¹⁹	Company	Approval Date
1	Cervarix ¹⁹ ⁵⁰	Human Papillomavirus Bivalent (Types 16 and 18) Vaccine, Recombinant	GlaxoSmithKline	October 2009
FDA Label: Cervarix Disease/s that Drug Treats:prevention of cervical cancer and cervical intraepithelial neoplasia caused by HPV types 16 and 18 Indications and Usage: ¹⁹ DrugBank Targets: - Mechanism of Action: ¹⁹ Target: IgG neutralizing antibodies directed against HPV-L1 capsid proteins Action: activates/ provokes production FDA: -
2	Gardasil ¹⁹ ⁵⁰	quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine	Merck	June 2006
FDA Label: Gardasil Disease/s that Drug Treats:Cervical Cancer Caused by Human Papillomavirus Indications and Usage: ¹⁹ GARDASIL is a vaccine indicated in girls and women 9 through 26years of age for the prevention of the following diseases caused byHuman Papillomavirus (HPV) types included in the vaccine: Cervical, vulvar, vaginal, and anal cancer caused by HPV types 16and 18 (1.1) Genital warts (condyloma acuminata) caused by HPV types 6 and11 (1.1)And the following precancerous or dysplastic lesions caused by HPVtypes 6, 11, 16, and 18: Cervical intraepithelial neoplasia (CIN) grade 2/3 and Cervicaladenocarcinoma in situ (AIS) (1.1) Cervical intraepithelial neoplasia (CIN) grade 1 (1.1) Vulvar intraepithelial neoplasia (VIN) grade 2 and grade 3 (1.1) Vaginal intraepithelial neoplasia (VaIN) grade 2 and grade 3 (1.1) Anal intraepithelial neoplasia (AIN) grades 1, 2, and 3 (1.1)GARDASIL is indicated in boys and men 9 through 26 years of age forthe prevention of the following diseases caused by HPV types includedin the vaccine: Anal cancer caused by HPV types 16 and 18 (1.2) Genital warts (condyloma acuminata) caused by HPV types 6 and11 (1.2)And the following precancerous or dysplastic lesions caused by HPVtypes 6, 11, 16, and 18: Anal intraepithelial neoplasia (AIN) grades 1, 2, and 3. (1.2)Limitations of GARDASIL Use and Effectiveness: GARDASIL does not eliminate the necessity for women tocontinue to undergo recommended cervical cancer screening.(1.3, 17) Recipients of GARDASIL should not discontinue anal cancerscreening if it has been recommended by a health care provider.(1.3, 17) GARDASIL has not been demonstrated to provide protectionagainst disease from vaccine and non-vaccine HPV types to whicha person has previously been exposed through sexual activity.(1.3, 14.4, 14.5) GARDASIL is not intended to be used for treatment of activeexternal genital lesions; cervical, vulvar, vaginal, and analcancers; CIN; VIN; VaIN, or AIN. (1.3) GARDASIL has not been demonstrated to protect againstdiseases due to HPV types not contained in the vaccine. (1.3,14.4, 14.5) Not all vulvar, vaginal, and anal cancers are caused by HPV, andGARDASIL protects only against those vulvar, vaginal, and analcancers caused by HPV 16 and 18. (1.3) GARDASIL does not protect against genital diseases not causedby HPV. (1.3) Vaccination with GARDASIL may not result in protection in allvaccine recipients. (1.3) GARDASIL has not been demonstrated to prevent HPV-relatedCIN 2/3 or worse in women older than 26 years of age. (14.7) DrugBank Targets: - Mechanism of Action: ¹⁹ Target: humoral immune response Action: inducer FDA: HPV only infects human beings. Animal studies with analogous animal papillomaviruses suggest thatthe efficacy of L1 VLP vaccines may involve the development of humoral immune responses. Humanbeings develop a humoral immune response to the vaccine, although the exact mechanism of protectionis unknown.

Drugs for Cervical Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 505)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Aluminum hydroxide

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1

21645-51-2

Bethanechol

Approved

Phase 4

674-38-4

2370

Peppermint

Approved

Phase 4

Cisplatin

Approved

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

15663-27-1

2767 441203 84093

Fentanyl

Approved, Illicit, Investigational, Vet_approved

Phase 4,Phase 3,Not Applicable

437-38-7

3345

Ritonavir

Approved, Investigational

Phase 4,Phase 3,Phase 2

155213-67-5

392622

Meperidine

Approved

Phase 4

57-42-1

4058

Diazepam

Approved, Illicit, Investigational, Vet_approved

Phase 4

439-14-5

3016

Iron

Approved, Experimental

Phase 4,Phase 1,Phase 2

7439-89-6, 15438-31-0

27284 23925

Ferrous fumarate

Approved

Phase 4

141-01-5

Polihexanide

Approved, Investigational

Phase 4

28757-47-3

Bupropion

Approved

Phase 4,Phase 2

34841-39-9, 34911-55-2

444

Dopamine

Approved

Phase 4,Phase 2

62-31-7, 51-61-6

681

Nicotine

Approved

Phase 4,Phase 1,Phase 2,Not Applicable,Early Phase 1

54-11-5

89594 942

Emtricitabine

Approved, Investigational

Phase 4

143491-57-0

60877

Tenofovir

Approved, Experimental, Investigational

Phase 4

147127-20-6

464205

Nevirapine

Approved

Phase 4

129618-40-2

4463

Vitamin C

Approved, Nutraceutical

Phase 4,Phase 2

50-81-7

54670067 5785

Vaccines

Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1

Immunologic Factors

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

Monophosphoryl lipid A

Phase 4

Cholinergic Agents

Phase 4,Phase 1,Phase 2,Not Applicable,Early Phase 1

Autonomic Agents

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

Neurotransmitter Agents

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

Peripheral Nervous System Agents

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

Muscarinic Agonists

Phase 4

Liver Extracts

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Antibodies

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Immunoglobulins

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Epoetin alfa

Phase 4,Phase 3

113427-24-0

Hematinics

Phase 4,Phase 3,Phase 2,Phase 1

Fluorodeoxyglucose F18

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Narcotics

Phase 4,Phase 3,Not Applicable,Early Phase 1

Anesthetics

Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1

Anesthetics, Intravenous

Phase 4,Phase 3,Not Applicable

Analgesics, Opioid

Phase 4,Phase 3,Not Applicable

Central Nervous System Depressants

Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1

Analgesics

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

Adjuvants, Anesthesia

Phase 4,Phase 3,Not Applicable

Anesthetics, General

Phase 4,Phase 3,Not Applicable

Nutrients

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Trace Elements

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Micronutrients

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Pharmaceutical Solutions

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Anti-Infective Agents

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

Psychotropic Drugs

Phase 4,Phase 3,Phase 2

Cytochrome P-450 Enzyme Inhibitors

Phase 4,Phase 3,Phase 2

HIV Protease Inhibitors

Phase 4,Phase 3,Phase 2,Phase 1

Cytochrome P-450 CYP3A Inhibitors

Phase 4,Phase 3,Phase 2

Antiviral Agents

Phase 4,Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 1434)

#	Name	Status	NCT ID	Phase	Drugs
1	The Efficacy of Tachosil® for Prevention of Hemorrhage After Loop Electrosurgical Excisional Procedure (LEEP)	Unknown status	NCT02629510	Phase 4	Tachosil
2	FASTER-Tlalpan Study	Unknown status	NCT03105856	Phase 4
3	Primary and Secondary Prevention of Human Papillomavirus (HPV) Disease in China	Unknown status	NCT01021904	Phase 4
4	Effectiveness of Bethanechol Chloride and Early Bladder Training for Prevention of Bladder Dysfunction After Radical Hysterectomy in Cervical Cancer Stage IB - IIA	Unknown status	NCT02910596	Phase 4	bethanechol chloride
5	Does the HPV Vaccine Cause the Same Response in Adolescent Kidney and Liver Transplant Patients as in Healthy Controls?	Unknown status	NCT01101750	Phase 4
6	Can Alternative Treatment Have an Impact on Cervical Dysplasia?	Unknown status	NCT00842738	Phase 4
7	Evaluation of Safety and Immunogenicity of a Human Papillomavirus (HPV) Vaccine in Human Immunodeficiency Virus (HIV) Infected Females	Unknown status	NCT01031069	Phase 4
8	Immunogenicity and Safety of Human Papilloma Virus Vaccine in Solid Organ Transplant Recipients	Unknown status	NCT02624349	Phase 4	Quadravalent human papillomavirus vaccine
9	Influence of Gum Chewing on Postoperative Bowel Activity After Complete Staging Surgery for Gynecological Malignancies	Unknown status	NCT01835119	Phase 4	gum
10	CervIcal Cancer Screening Trial by Randomization of HPV Testing Intervention for Upcoming Screening （CITRUS Study）	Active, not recruiting	NCT01895517	Phase 4
11	Dissemination of Cervical Cancer Screening to Primary Care Physicians in Underserved Communities	Terminated	NCT00629993	Phase 4
12	To Evaluate the Efficacy and Safety of PEG-rhG-CSF（Jinyouli®） in Reducing Neutropenia in Patients With Cervical Cancer	Not yet recruiting	NCT03206684	Phase 4	PEG-rhG-CSF;rhG-CSF
13	Epoetin Beta in Treating Anemia in Patients With Cervical Cancer	Completed	NCT00046969	Phase 4	cisplatin
14	Effect of HPV Vaccination on Women Aged 25 Years	Completed	NCT02296255	Phase 4
15	Comparing Health Services Interventions for the Prevention of HPV-related Cancer	Completed	NCT02837926	Phase 4
16	Patient Navigation in the Safety Net:CONNECTeDD	Completed	NCT00613275	Phase 4
17	Scientific Evaluation of One or Two Doses of the Bivalent or Nonavalent Prophylactic HPV Vaccines	Recruiting	NCT03180034	Phase 4
18	V501 Safety and Efficacy Study in Japanese Women Aged 16 to 26 Years (V501-110)	Completed	NCT01544478	Phase 4
19	Pilot Study to Assess the Potential Clinical Utility of 18F Fluciclovine PET for Cervical and Endometrial Cancer.	Recruiting	NCT03423082	Phase 4	18F fluciclovine
20	Application of Tachosil During Lymphadenectomy	Completed	NCT03752606	Phase 4
21	Delivery, Uptake and Acceptability of HPV Vaccination in Tanzanian Girls	Completed	NCT01173900	Phase 4
22	Alternate Dosing Schedules Study for HPV Vaccine	Completed	NCT00862810	Phase 4
23	Evaluation of Long-term Immunogenicity and Safety of a Human Papillomavirus (HPV) Vaccine in Healthy Female Subjects	Completed	NCT00947115	Phase 4
24	A Study to Assess the Safety and Reactogenicity of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (HPV) Vaccine (Cervarix) in Healthy Female Filipino Subjects Vaccinated According to the Prescribing Information From the Age of 10 Years Onwards.	Terminated	NCT00730847	Phase 4
25	Trial of Two Versus Three Doses of Human Papillomavirus (HPV) Vaccine in India	Active, not recruiting	NCT00923702	Phase 4
26	Reactogenicity Study of Cervarix and Gardasil in UK Adolescent Girls	Completed	NCT00956553	Phase 4
27	Comparison of Meperidine and Fentanyl on Pain Scale and QOL in Brachytherapy	Completed	NCT02684942	Phase 4	Meperidine;Fentanyl
28	The KEN SHE Study on HPV-vaccine Efficacy	Enrolling by invitation	NCT03675256	Phase 4
29	Evaluation of Fluciclovine Uptake in Patients With Cervical, Ovarian Epithelial or Endometrial Cancers.	Recruiting	NCT03349463	Phase 4	Fluciclovine F18
30	Oral Iron vs. Placebo in Newly Diagnosed Gynecologic Oncology Patients Who Are Surgical Candidates.	Active, not recruiting	NCT01953107	Phase 4
31	Effectiveness, Safety and Immunogenicity of GSK Biologicals' HPV Vaccine GSK580299 (Cervarix TM) Administered in Healthy Adolescents	Completed	NCT00534638	Phase 4
32	Transmission Reduction and Prevention With HPV Vaccination (TRAP-HPV) Study	Recruiting	NCT01824537	Phase 4
33	Immune Response After Human Papillomavirus Vaccination in Patients With Autoimmune Disease	Completed	NCT00815282	Phase 4
34	Polyhexamethylene Biguanide Increases the Regression Rate of Human Papillomavirus (HPV) Infection	Completed	NCT01571141	Phase 4
35	Postpartum HPV Vaccination	Recruiting	NCT03451071	Phase 4	Gardasil9
36	Health Education Counseling With or Without Bupropion in Helping African Americans Stop Smoking	Completed	NCT00666978	Phase 4	bupropion hydrochloride
37	Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking	Completed	NCT00365508	Phase 4	nicotine lozenge;nicotine patch
38	Safety and Protective Effect Study of GSK Biologicals' Human Papillomavirus (Types 16, 18) Vaccine, Adsorbed (GSK580299) in Healthy Female Subjects From the HPV-039 Study	Active, not recruiting	NCT03629886	Phase 4
39	The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies.	Completed	NCT03384511	Phase 4	Apatinib
40	Nevirapine vs. Atazanavir Boosted With Ritonavir on a Background of Truvada in Human Immunodeficiency Virus (HIV) Infected Naive Patients (NEwArT)	Completed	NCT00552240	Phase 4	tenofovir DF 300 mg QD;tenofovir DF 300 mg QD;emtricitabine 200 mg QD;emtricitabine 200 mg QD;Nevirapine 200 mg BID;Atazanavir 300 mg;Ritonavir 100 mg
41	Cisplatin Based Chemoradiation v.s Radiotherapy for Cervical Cancer and With Clinically Defined Good Prognosis	Unknown status	NCT00846508	Phase 3	Cisplatin
42	Randomized Trial Between Weekly and 5 Day 3 Weekly Cisplatin for Cervical Cancer	Unknown status	NCT00548821	Phase 3	Cisplatin
43	Evaluation of TRANSKRIP ® Plus Chemotherapy in Recurrent-Persistent Cervical Cancer	Unknown status	NCT02446652	Phase 3	Hydralazine/Magnesium;Placebo;Carboplatin;Paclitaxel
44	Adjuvant Chemotherapy for Locally Advanced Cervical Cancer	Unknown status	NCT02036164	Phase 3	Cisplatin;Paclitaxel;Carboplatin
45	Postoperative Chemoradiation v.s Radiotherapy for Lymph Node Negative Cervical Cancer Patients	Unknown status	NCT01756170	Phase 3	paclitaxel;cisplatin
46	Radiotherapy With Single-Agent Cisplatin or Combination Chemotherapy in Defined Poor-Prognostic Cervical Cancer	Unknown status	NCT00842660	Phase 3	Gemzar (gemcitabine)
47	Trial of Postoperative Chemoradiotherapy With or Without Consolidation Chemotherapy for Cervical Cancer Patients	Unknown status	NCT01755845	Phase 3	paclitaxel;cisplatin
48	Evaluation of Postoperative Radiotherapy and Concurrent Chemotherapy Effectiveness in Cervical Cancer	Unknown status	NCT01999933	Phase 2, Phase 3	cisplatin（DDP） weekly;docetaxel plus cisplatin;docetaxel plus cisplatin
49	Usefulness of FDG-PET for Advanced Cervical Cancer	Unknown status	NCT00146458	Phase 3
50	Hydralazine Valproate for Cervical Cancer	Unknown status	NCT00532818	Phase 3	Hydralazine and magnesium valproate;Placebo

Search NIH Clinical Center for Cervical Cancer

Cochrane evidence based reviews: uterine cervical neoplasms

Sources

Genetic Tests for Cervical Cancer

Sources

Anatomical Context for Cervical Cancer

MalaCards organs/tissues related to Cervical Cancer:

⁴²

Cervix, Testes, Lymph Node, Breast, T Cells, Lung, Uterus

The Foundational Model of Anatomy Ontology organs/tissues related to Cervical Cancer:

²⁰

The Cervix

Sources

Publications for Cervical Cancer

Articles related to Cervical Cancer:

(show top 50) (show all 7360)

#	Title	Authors	Year
1	Long non-coding RNA metastasis-associated lung adenocarcinoma transcript 1/microRNA-202-3p/periostin axis modulates invasion and epithelial-mesenchymal transition in human cervical cancer. ( 30633360 )	Han X...Wang W	2019
2	Adenocarcinoma histology is a poor prognostic factor in locally advanced cervical cancer. ( 30019594 )	Jonska-Gmyrek J...Kotowicz B	2019
3	Cost-effectiveness of breast cancer screening in the National Breast and Cervical Cancer Early Detection Program. ( 31098856 )	Rim SH...Hoerger TJ	2019
4	Cardiac Tamponade as an Initial Manifestation of Cervical Cancer. ( 30729054 )	Rodr?guez-Rosales YE...G?mez-Mac?as GS	2019
5	SURVIVAL OUTCOMES OF ROBOTIC RADICAL HYSTERECTOMY FOR EARLY STAGE CERVICAL CANCER: A 9-YEAR STUDY. ( 31039279 )	Siesto G...Vitobello D	2019
6	The proliferation of cervical cancer is promoted by miRNA-125b through the regulation of the HMGA1. ( 31043793 )	Sun B...Xia J	2019
7	Moving toward the elimination of cervical cancer: modelling the health and economic benefits of increasing uptake of human papillomavirus vaccines. ( 31043805 )	Smith A...Bryant H	2019
8	Towards global elimination of cervical cancer in all groups of women. ( 31044712 )	Kumar P...Das BC	2019
9	Towards global elimination of cervical cancer in all groups of women. ( 31044713 )	Whop LJ...Condon JR	2019
10	Towards global elimination of cervical cancer in all groups of women - Authors' reply. ( 31044714 )	Simms KT...Canfell K	2019
11	Barriers to Cervical Cancer Screening and Treatment in the Dominican Republic: Perspectives of Focus Group Participants in the Santo Domingo Area. ( 31046602 )	Liebermann EJ...Ompad D	2019
12	Smoking Cessation Treatment Needs of Low SES Cervical Cancer Survivors. ( 31046890 )	Hoover DS...Wetter DW	2019
13	Thymosin β-4 is a novel regulator for primary cilium formation by nephronophthisis 3 in HeLa human cervical cancer cells. ( 31048733 )	Lee JW...Moon EY	2019
14	Downregulation of microRNA-205 inhibits cell invasion and angiogenesis of cervical cancer through TSLC1-mediated Akt signaling pathway. ( 31049956 )	Zhang F...Xie BB	2019
15	Cervical cancer - causes and prevention of hpv infections in the opinions of young polish women: a cross-sectional survey. ( 31050976 )	Kotowski A...Fal AM	2019
16	Optimisation of Folate-Mediated Liposomal Encapsulated Arsenic Trioxide for Treating HPV-Positive Cervical Cancer Cells In Vitro. ( 31052347 )	Akhtar A...Wen X	2019
17	Years of Life Lost Due to Cervical Cancer in Poland in 2000 to 2015. ( 31052396 )	Pikala M...Maniecka-Bry?a I	2019
18	Re-thinking breast and cervical cancer preventive campaigns in developing countries: the case for interventions at high schools. ( 31053073 )	Ifediora CO	2019
19	Knowledge, attitudes and practices of cervical cancer prevention among Zambian women and men. ( 31054569 )	Nyambe A...Van Hal G	2019
20	Osthole promotes the suppressive effects of cisplatin on NRF2 expression to prevent drug-resistant cervical cancer progression. ( 31056260 )	Su J...Liu Z	2019
21	Modelling risk assessment for cervical cancer in symptomatic Saudi women. ( 31056620 )	Al-Madani W...Jazieh AR	2019
22	Simultaneous Metastasis from Cervical Cancer to the Kidney and Paraspinal Muscle: A Case Report. ( 31058031 )	Rodriguez J...Pareja R	2019
23	Simvastatin enhances chemotherapy in cervical cancer via inhibition of multiple prenylation-dependent GTPases-regulated pathways. ( 31058344 )	Pan Q...Ma L	2019
24	PI3K/AKT/mTOR Signaling Regulates the Virus/Host Cell Crosstalk in HPV-Positive Cervical Cancer Cells. ( 31058807 )	Bossler F...Hoppe-Seyler F	2019
25	Serum bradykinin levels as a diagnostic marker in cervical cancer with a potential mechanism to promote VEGF expression via BDKRB2. ( 31059006 )	Zhou Y...Xi L	2019
26	S100A9 promotes the proliferation and migration of cervical cancer cells by inducing epithelial‑mesenchymal transition and activating the Wnt/β‑catenin pathway. ( 31059008 )	Zha H...Zhou L	2019
27	microRNA-944 overexpression is a biomarker for poor prognosis of advanced cervical cancer. ( 31060525 )	Park S...Lee H	2019
28	Short- and long term outcomes after abdominal radical trachelectomy versus radical hysterectomy for early stage cervical cancer: a systematic review of the literature and meta-analysis. ( 31062151 )	Prodromidou A...Kalinoglou N	2019
29	Integrated analysis of two-lncRNA signature as a potential prognostic biomarker in cervical cancer: a study based on public database. ( 31065456 )	Wu W...Liang G	2019
30	Comparing Receipt of Cervical Cancer Screening and Completion of Human Papillomavirus Vaccination Using a New Construct of Sexual Orientation: A Serial Cross-Sectional Study. ( 31066610 )	Porsch LM...Dean G	2019
31	Cervical cancer - staging and restaging with 18F-FDG PET/CT. ( 31066810 )	Brito AET...Bernardo WM	2019
32	Treatment Compliance as a Major Barrier to Optimal Cervical Cancer Treatment in Guatemala. ( 31067142 )	Zamorano AS...Mutch DG	2019
33	Role of Human Papillomavirus DNA Load in Predicting the Long-term Risk of Cervical Cancer: A 15-Year Prospective Cohort Study in China. ( 31067317 )	Zhao X...Zhao F	2019
34	AgNOR Pleomorphic Count as a Tumor Marker in Cervical Carcinogenesis and Feasibility of Its Introduction in Cervical Cancer Screening Programs to Discriminate High-Risk Cases of Squamous Intraepithelial Lesions of the Cervix. ( 31067531 )	Srivastava AN...Raza S	2019
35	Enhanced anticancer effects of a methylation inhibitor by inhibiting a novel DNMT1 target, CEP 131, in cervical cancer. ( 31068247 )	Kim DH...Kim BY	2019
36	Increased bone marrow SUVmax on 18F-FDG PET is associated with higher pelvic treatment failure in patients with cervical cancer treated by chemoradiotherapy and brachytherapy. ( 31069132 )	Seban RD...Deutsch E	2019
37	Evaluation of cytology as secondary triage in visual inspection after application of 4% acetic acid-based cervical cancer screening program. ( 31069189 )	Mishra GA...Gupta SD	2019
38	Second primary uterine malignancies after radiation therapy for cervical cancer. ( 31069490 )	Papatla K...Rubin S	2019
39	Contrast-Enhancing Snapshot Narrow-Band Imaging Method for Real-Time Computer-Aided Cervical Cancer Screening. ( 31069586 )	Yi D...Zhao Y	2019
40	Stereotactic body radiation therapy for oligometastatic pulmonary tumors from cervical cancer. ( 31070018 )	Hou X...Hu K	2019
41	Using Low-Cost Virtual Reality Simulation to Build Surgical Capacity for Cervical Cancer Treatment. ( 31070982 )	Bing EG...Sullivan R	2019
42	Correction: ΔNp63 to TAp63 expression ratio as a potential molecular marker for cervical cancer prognosis. ( 31071170 )	Park S...Lee H	2019
43	Assessment of epigenetic alterations and in silico analysis of mutation affecting PTEN expression among Indian cervical cancer patients. ( 31074114 )	Naseem A...Alam Rizvi MM	2019
44	Stage and histology of cervical cancer in women under 25 years old. ( 31074235 )	Vale DB...Zeferino LC	2019
45	A randomized controlled trial comparing concurrent chemoradiation versus concurrent chemoradiation followed by adjuvant chemotherapy in locally advanced cervical cancer patients: ACTLACC trial. ( 31074236 )	Tangjitgamol S...Lorvidhaya V	2019
46	A community-based, cross-sectional study of hrHPV DNA self-sampling-based cervical cancer screening in rural Karnataka, India. ( 31074835 )	Adsul P...Madhivanan P	2019
47	Effect of Deubiquitinase Ovarian Tumor Domain-Containing Protein 5 (OTUD5) on Radiosensitivity of Cervical Cancer by Regulating the Ubiquitination of Akt and its Mechanism. ( 31075090 )	Yin F...Cui H	2019
48	Cervical cancer screening knowledge and barriers among women in Addis Ababa, Ethiopia. ( 31075122 )	Getachew S...Kantelhardt EJ	2019
49	Clinical Outcomes in Early Cervical Cancer Patients Treated with Nerve Plane-Sparing Laparoscopic Radical Hysterectomy. ( 31075445 )	Zhao D...Yuan G	2019
50	Fertility-sparing surgery for early-stage cervical cancer: does surgical approach have an impact on disease outcomes? ( 31076039 )	Bixel KL...Fowler JM	2019

Sources

Genes for Cervical Cancer

Genes related to Cervical Cancer (14 elite genes):

(show top 50) (show all 153)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubmedIds
1	FGFR3	Fibroblast Growth Factor Receptor 3	Protein Coding	1241.51	Molecular basis known ⁵⁸ Pathogenic ⁶ Causative variation ⁷⁶ DISEASES inferred ¹⁵ Novoseek inferred ⁵⁶ GeneCards inferred via : Disorders Publications Variants (show sections)	11114733 18794123 15105428
2	PIK3CA	Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha	Protein Coding	441.02	Pathogenic ⁶ Pathogenic/Likely pathogenic ⁶ DISEASES inferred ¹⁵ Novoseek inferred ⁵⁶ GeneCards inferred via : Publications (show sections)	18180098 16391859
3	CTNNB1	Catenin Beta 1	Protein Coding	438.13	Pathogenic/Likely pathogenic ⁶ DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
4	TP53	Tumor Protein P53	Protein Coding	435.19	Pathogenic ⁶ DISEASES inferred ¹⁵ Novoseek inferred ⁵⁶ GeneCards inferred via : Publications (show sections)	16681751 14756543 10895031 (more) 12445252 17375700 11535556 15908516 11836622 16481734 12144822 10794489 14764039 12618167 8674566 1349102 20200430 8774641 10754463 8806692 15640620 9742979 19625214 15899386 18313527 16761419 15790450 14529662 12144687 17012841 17178878 10726657 8942499 1322252 11429213 9155557 16488468 17912468 11485021 11174479 7909855 10741285 10775508 10918193 12451999 17192686 17177838 12821336 12713987 16544983 16054204 15994823 14678586 12499281 10023783 8674061 16841142 18599197 11158620 11212257 10618709 9367711 7591279 8172533 20167600 19423538 15581977 15073118 12534455 11996107 10928171 11885807 8546000 7962045 8397367 19012699 16324714 15905603 15797321 15566643 8623835 8388491 16287099 15143339 12406566 10975290 10729761 9704765 9334921 8039779 11072671 10760422 7841033 1933850 17713095 17324262 15047208 14513722 11146234 15863130
5	AKT1	AKT Serine/Threonine Kinase 1	Protein Coding	413.6	Pathogenic/Likely pathogenic ⁶ DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
6	SMAD4	SMAD Family Member 4	Protein Coding	413.4	Pathogenic ⁶ DISEASES inferred ¹⁵ Novoseek inferred ⁵⁶ GeneCards inferred via : Publications (show sections)	18425078 12894231 17997817 (more) 16269171 15531914 11745435
7	PTEN	Phosphatase And Tensin Homolog	Protein Coding	412.69	Pathogenic ⁶ DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
7	PTEN::MIR21 ⁴⁸	MIR21 Macro RNA (hsa-miR-21) targets PTEN
8	ERBB2	Erb-B2 Receptor Tyrosine Kinase 2	Protein Coding	412.46	Pathogenic/Likely pathogenic ⁶ DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
9	MTOR	Mechanistic Target Of Rapamycin Kinase	Protein Coding	411.67	Pathogenic/Likely pathogenic ⁶ DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
10	HRAS	HRas Proto-Oncogene, GTPase	Protein Coding	411.44	Pathogenic ⁶ DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
11	MIR21	MicroRNA 21	RNA Gene	407.43	Causal ⁴⁸ Unspecified ⁴⁸ GeneCards inferred via : Publications (show sections)	19682430 17616659
12	NFE2L2	Nuclear Factor, Erythroid 2 Like 2	Protein Coding	406.42	Pathogenic/Likely pathogenic ⁶ GeneCards inferred via : Publications (show sections)
13	GNAS	GNAS Complex Locus	Protein Coding	400	Pathogenic/Likely pathogenic ⁶
14	MIR214	MicroRNA 214	RNA Gene	356.97	Causal ⁴⁸ GeneCards inferred via : Publications (show sections)	19859982
15	TMPOP2	Thymopoietin Pseudogene 2	Pseudogene	165	Experimental evidence: Regulation ⁴⁰ GeneCards inferred via : Publications Gene name (show sections)	25007342
16	CCND1	Cyclin D1	Protein Coding	163.56	Experimental evidence: Regulation ⁴⁰ DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)	22487937
17	HOTAIR	HOX Transcript Antisense RNA	RNA Gene	162.84	Experimental evidence: Regulation ⁴⁰ DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)	29572071 29336659 29335299 (more) 28745272 28600545 27897239 27736969 27683269 27574106 27467165 27323817 27229487 27184657 26523512 26152361 26109871 25547435 25405331 25366139 24748337 22487937
18	STAT3	Signal Transducer And Activator Of Transcription 3	Protein Coding	162.6	Experimental evidence: Regulation ⁴⁰ DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)	29572071
19	CCEPR	Cervical Carcinoma Expressed PCNA Regulatory LncRNA	RNA Gene	160.87	Experimental evidence: Expression ⁴⁰ DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)	29427865 28239824 25921283
20	PVT1	Pvt1 Oncogene	RNA Gene	160.81	Experimental evidence: Interaction ⁴⁰ DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)	28276314 27775803 27272214 (more) 27232880
21	GAS5	Growth Arrest Specific 5	RNA Gene	160.56	Experimental evidence: Interaction ⁴⁰ DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)	28671039 28472815 25400758 (more) 22487937
22	NEAT1	Nuclear Paraspeckle Assembly Transcript 1	RNA Gene	160.47	Experimental evidence: Expression ⁴⁰ DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)	29207151
23	CDKN2B-AS1	CDKN2B Antisense RNA 1	RNA Gene	160.03	Experimental evidence: Interaction ⁴⁰ DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)	28550682 27899255 26408699 (more) 22487937
24	ZNF667-AS1	ZNF667 Antisense RNA 1 (Head To Head)	RNA Gene	159.81	Experimental evidence: Expression ⁴⁰ DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)	29243775
25	HOXA11-AS	HOXA11 Antisense RNA	RNA Gene	159.7	Experimental evidence: Regulation ⁴⁰ DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)	27792998
26	CCAT1	Colon Cancer Associated Transcript 1	RNA Gene	159.44	Experimental evidence: Regulation ⁴⁰ DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)	28978096 28849215
27	BCAR4	Breast Cancer Anti-Estrogen Resistance 4	RNA Gene	159.36	Experimental evidence: Interaction ⁴⁰ DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)	28112728
28	HAGLR	HOXD Antisense Growth-Associated Long Non-Coding RNA	RNA Gene	159.3	Experimental evidence: Regulation ⁴⁰ DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
29	H19	H19 Imprinted Maternally Expressed Transcript	RNA Gene	158.46	Experimental evidence: Regulation ⁴⁰ Novoseek inferred ⁵⁶ GeneCards inferred via : Publications (show sections)	15525575 8570220 8570220
30	MALAT1	Metastasis Associated Lung Adenocarcinoma Transcript 1	RNA Gene	156.88	Experimental evidence: Expression ⁴⁰ GeneCards inferred via : Publications (show sections)	27658300 27184657 26854446 (more) 26798987 26400521 26311052 26242259 25773124 24932303 24757675 22664915 22491206 22487937 21266177 20213048
31	MEG3	Maternally Expressed 3	RNA Gene	156.62	Experimental evidence: Regulation ⁴⁰ GeneCards inferred via : Publications (show sections)	29620291 28057015 27184657 (more) 26574780 23790166 22487937 14602737
32	TUG1	Taurine Up-Regulated 1	RNA Gene	156.42	Experimental evidence: Regulation ⁴⁰ GeneCards inferred via : Publications (show sections)	29029428 28088836
33	UCA1	Urothelial Cancer Associated 1	RNA Gene	156.42	Experimental evidence: Regulation ⁴⁰ GeneCards inferred via : Publications (show sections)	29523226 28414550 17416635 (more) 16914571
34	HULC	Hepatocellular Carcinoma Up-Regulated Long Non-Coding RNA	RNA Gene	156.07	Experimental evidence: Expression ⁴⁰ GeneCards inferred via : Publications (show sections)	27775802
35	CRNDE	Colorectal Neoplasia Differentially Expressed	Protein Coding	156.07	Experimental evidence: Expression ⁴⁰ GeneCards inferred via : Publications (show sections)	29194035
36	CCAT2	Colon Cancer Associated Transcript 2	RNA Gene	156.07	Experimental evidence: Regulation ⁴⁰ GeneCards inferred via : Publications (show sections)	26983975
37	TUSC8	Tumor Suppressor Candidate 8	RNA Gene	154.83	Experimental evidence: Regulation ⁴⁰ DISEASES inferred ¹⁵	24667250
38	BLACAT1	Bladder Cancer Associated Transcript 1	RNA Gene	154.27	Experimental evidence: Expression ⁴⁰ DISEASES inferred ¹⁵	29456724
39	ENSG00000249626		Pseudogene	154.23	Experimental evidence: Expression ⁴⁰ DISEASES inferred ¹⁵	27035672
40	LINC01101	Long Intergenic Non-Protein Coding RNA 1101	RNA Gene	154.17	Experimental evidence: Expression ⁴⁰ DISEASES inferred ¹⁵	28767188
41	MIR9-3HG	MIR9-3 Host Gene	RNA Gene	154.17	Experimental evidence: Regulation ⁴⁰ DISEASES inferred ¹⁵	29620291
42	SNHG12	Small Nucleolar RNA Host Gene 12	RNA Gene	153.44	Experimental evidence: Regulation ⁴⁰ DISEASES inferred ¹⁵	29533945
43	PAX8-AS1	PAX8 Antisense RNA 1	RNA Gene	153.36	Experimental evidence: Expression ⁴⁰ DISEASES inferred ¹⁵	27225188
44	SNHG16	Small Nucleolar RNA Host Gene 16	RNA Gene	153.14	Experimental evidence: Interaction ⁴⁰ DISEASES inferred ¹⁵	29126969
45	ZNRD1ASP	Zinc Ribbon Domain Containing 1 Antisense, Pseudogene	Pseudogene	153.1	Experimental evidence: Expression ⁴⁰ DISEASES inferred ¹⁵	26328261
46	EWSAT1	Ewing Sarcoma Associated Transcript 1	RNA Gene	152.94	Experimental evidence: Expression ⁴⁰ DISEASES inferred ¹⁵	28767188
47	RNY1	RNA, Ro60-Associated Y1	RNA Gene	150	Experimental evidence: Regulation ⁴⁰	18283318
48	BCYRN1	Brain Cytoplasmic RNA 1	RNA Gene	150	Experimental evidence: Regulation ⁴⁰	29552212 9422992
49	HTATIP2	HIV-1 Tat Interactive Protein 2	Protein Coding	150	Experimental evidence: Regulation ⁴⁰	27223436
50	LINP1	LncRNA In Non-Homologous End Joining Pathway 1	RNA Gene	150	Experimental evidence: Interaction ⁴⁰	29527968

Sources

Variations for Cervical Cancer

UniProtKB/Swiss-Prot genetic disease variations for Cervical Cancer:

⁷⁶

#	Symbol	AA change	Variation ID	SNP ID
1	FGFR3	p.Ser249Cys	VAR_004149	rs121913483

ClinVar genetic disease variations for Cervical Cancer:

⁶ (show top 50) (show all 286)

#	Gene	Variation	Type	Significance	SNP ID	Assembly	Location
1	PTEN	NM_000314.4(PTEN): c.389G> A (p.Arg130Gln)	single nucleotide variant	Pathogenic	rs121909229	GRCh37	Chromosome 10, 89692905: 89692905
2	PTEN	NM_000314.4(PTEN): c.389G> A (p.Arg130Gln)	single nucleotide variant	Pathogenic	rs121909229	GRCh38	Chromosome 10, 87933148: 87933148
3	SMAD4	NM_005359.5(SMAD4): c.1081C> T (p.Arg361Cys)	single nucleotide variant	Pathogenic	rs80338963	GRCh37	Chromosome 18, 48591918: 48591918
4	SMAD4	NM_005359.5(SMAD4): c.1081C> T (p.Arg361Cys)	single nucleotide variant	Pathogenic	rs80338963	GRCh38	Chromosome 18, 51065548: 51065548
5	TP53	NM_000546.5(TP53): c.747G> T (p.Arg249Ser)	single nucleotide variant	Conflicting interpretations of pathogenicity	rs28934571	GRCh37	Chromosome 17, 7577534: 7577534
6	TP53	NM_000546.5(TP53): c.747G> T (p.Arg249Ser)	single nucleotide variant	Conflicting interpretations of pathogenicity	rs28934571	GRCh38	Chromosome 17, 7674216: 7674216
7	TP53	NM_000546.5(TP53): c.839G> C (p.Arg280Thr)	single nucleotide variant	Uncertain significance	rs121912660	GRCh37	Chromosome 17, 7577099: 7577099
8	TP53	NM_000546.5(TP53): c.839G> C (p.Arg280Thr)	single nucleotide variant	Uncertain significance	rs121912660	GRCh38	Chromosome 17, 7673781: 7673781
9	HRAS	NM_176795.4(HRAS): c.34G> A (p.Gly12Ser)	single nucleotide variant	Pathogenic	rs104894229	GRCh37	Chromosome 11, 534289: 534289
10	HRAS	NM_176795.4(HRAS): c.34G> A (p.Gly12Ser)	single nucleotide variant	Pathogenic	rs104894229	GRCh38	Chromosome 11, 534289: 534289
11	HRAS	NM_005343.3(HRAS): c.437C> T (p.Ala146Val)	single nucleotide variant	Likely pathogenic	rs121917759	GRCh38	Chromosome 11, 533466: 533466
12	HRAS	NM_005343.2(HRAS): c.35G> C (p.Gly12Ala)	single nucleotide variant	Pathogenic	rs104894230	GRCh37	Chromosome 11, 534288: 534288
13	HRAS	NM_005343.3(HRAS): c.437C> T (p.Ala146Val)	single nucleotide variant	Likely pathogenic	rs121917759	GRCh37	Chromosome 11, 533466: 533466
14	HRAS	NM_005343.2(HRAS): c.35G> C (p.Gly12Ala)	single nucleotide variant	Pathogenic	rs104894230	GRCh38	Chromosome 11, 534288: 534288
15	HRAS	NM_005343.4(HRAS): c.37G> T (p.Gly13Cys)	single nucleotide variant	Pathogenic	rs104894228	GRCh37	Chromosome 11, 534286: 534286
16	HRAS	NM_005343.4(HRAS): c.37G> T (p.Gly13Cys)	single nucleotide variant	Pathogenic	rs104894228	GRCh38	Chromosome 11, 534286: 534286
17	HRAS	NM_005343.3(HRAS): c.436G> A (p.Ala146Thr)	single nucleotide variant	Pathogenic/Likely pathogenic	rs104894231	GRCh37	Chromosome 11, 533467: 533467
18	HRAS	NM_005343.3(HRAS): c.436G> A (p.Ala146Thr)	single nucleotide variant	Pathogenic/Likely pathogenic	rs104894231	GRCh38	Chromosome 11, 533467: 533467
19	HRAS	NM_005343.2(HRAS): c.34G> T (p.Gly12Cys)	single nucleotide variant	Pathogenic	rs104894229	GRCh37	Chromosome 11, 534289: 534289
20	HRAS	NM_005343.2(HRAS): c.34G> T (p.Gly12Cys)	single nucleotide variant	Pathogenic	rs104894229	GRCh38	Chromosome 11, 534289: 534289
21	PIK3CA	NM_006218.4(PIK3CA): c.3140A> G (p.His1047Arg)	single nucleotide variant	Pathogenic	rs121913279	GRCh37	Chromosome 3, 178952085: 178952085
22	PIK3CA	NM_006218.4(PIK3CA): c.3140A> G (p.His1047Arg)	single nucleotide variant	Pathogenic	rs121913279	GRCh38	Chromosome 3, 179234297: 179234297
23	PIK3CA	NM_006218.3(PIK3CA): c.3140A> T (p.His1047Leu)	single nucleotide variant	Pathogenic	rs121913279	GRCh37	Chromosome 3, 178952085: 178952085
24	PIK3CA	NM_006218.3(PIK3CA): c.3140A> T (p.His1047Leu)	single nucleotide variant	Pathogenic	rs121913279	GRCh38	Chromosome 3, 179234297: 179234297
25	PIK3CA	NM_006218.3(PIK3CA): c.1636C> G (p.Gln546Glu)	single nucleotide variant	Pathogenic/Likely pathogenic	rs121913286	GRCh37	Chromosome 3, 178936094: 178936094
26	PIK3CA	NM_006218.3(PIK3CA): c.1636C> G (p.Gln546Glu)	single nucleotide variant	Pathogenic/Likely pathogenic	rs121913286	GRCh38	Chromosome 3, 179218306: 179218306
27	PIK3CA	NM_006218.3(PIK3CA): c.1633G> A (p.Glu545Lys)	single nucleotide variant	Pathogenic/Likely pathogenic	rs104886003	GRCh37	Chromosome 3, 178936091: 178936091
28	PIK3CA	NM_006218.3(PIK3CA): c.1633G> A (p.Glu545Lys)	single nucleotide variant	Pathogenic/Likely pathogenic	rs104886003	GRCh38	Chromosome 3, 179218303: 179218303
29	PIK3CA	NM_006218.3(PIK3CA): c.1633G> A (p.Glu545Lys)	single nucleotide variant	Pathogenic/Likely pathogenic	rs104886003	NCBI36	Chromosome 3, 180418785: 180418785
30	PIK3CA	NM_006218.3(PIK3CA): c.1634A> G (p.Glu545Gly)	single nucleotide variant	Pathogenic/Likely pathogenic	rs121913274	GRCh37	Chromosome 3, 178936092: 178936092
31	PIK3CA	NM_006218.3(PIK3CA): c.1634A> G (p.Glu545Gly)	single nucleotide variant	Pathogenic/Likely pathogenic	rs121913274	GRCh38	Chromosome 3, 179218304: 179218304
32	PIK3CA	NM_006218.3(PIK3CA): c.1636C> A (p.Gln546Lys)	single nucleotide variant	Pathogenic/Likely pathogenic	rs121913286	GRCh37	Chromosome 3, 178936094: 178936094
33	PIK3CA	NM_006218.3(PIK3CA): c.1636C> A (p.Gln546Lys)	single nucleotide variant	Pathogenic/Likely pathogenic	rs121913286	GRCh38	Chromosome 3, 179218306: 179218306
34	PIK3CA	NM_006218.3(PIK3CA): c.1634A> C (p.Glu545Ala)	single nucleotide variant	Pathogenic	rs121913274	GRCh37	Chromosome 3, 178936092: 178936092
35	PIK3CA	NM_006218.3(PIK3CA): c.1634A> C (p.Glu545Ala)	single nucleotide variant	Pathogenic	rs121913274	GRCh38	Chromosome 3, 179218304: 179218304
36	AKT1	NM_005163.2(AKT1): c.49G> A (p.Glu17Lys)	single nucleotide variant	Pathogenic/Likely pathogenic	rs121434592	GRCh37	Chromosome 14, 105246551: 105246551
37	AKT1	NM_005163.2(AKT1): c.49G> A (p.Glu17Lys)	single nucleotide variant	Pathogenic/Likely pathogenic	rs121434592	GRCh38	Chromosome 14, 104780214: 104780214
38	GNAS	NM_000516.5(GNAS): c.601C> T (p.Arg201Cys)	single nucleotide variant	Pathogenic/Likely pathogenic	rs11554273	GRCh37	Chromosome 20, 57484420: 57484420
39	GNAS	NM_000516.5(GNAS): c.601C> T (p.Arg201Cys)	single nucleotide variant	Pathogenic/Likely pathogenic	rs11554273	GRCh38	Chromosome 20, 58909365: 58909365
40	GNAS	NM_000516.5(GNAS): c.602G> A (p.Arg201His)	single nucleotide variant	Pathogenic/Likely pathogenic	rs121913495	GRCh37	Chromosome 20, 57484421: 57484421
41	GNAS	NM_000516.5(GNAS): c.602G> A (p.Arg201His)	single nucleotide variant	Pathogenic/Likely pathogenic	rs121913495	GRCh38	Chromosome 20, 58909366: 58909366
42	FGFR3	NM_000142.4(FGFR3): c.1138G> A (p.Gly380Arg)	single nucleotide variant	Conflicting interpretations of pathogenicity	rs28931614	GRCh37	Chromosome 4, 1806119: 1806119
43	FGFR3	NM_000142.4(FGFR3): c.1138G> A (p.Gly380Arg)	single nucleotide variant	Conflicting interpretations of pathogenicity	rs28931614	GRCh38	Chromosome 4, 1804392: 1804392
44	FGFR3	NM_000142.4(FGFR3): c.742C> T (p.Arg248Cys)	single nucleotide variant	Pathogenic	rs121913482	GRCh37	Chromosome 4, 1803564: 1803564
45	FGFR3	NM_000142.4(FGFR3): c.742C> T (p.Arg248Cys)	single nucleotide variant	Pathogenic	rs121913482	GRCh38	Chromosome 4, 1801837: 1801837
46	FGFR3	NM_001163213.1(FGFR3): c.1626C> G (p.Asn542Lys)	single nucleotide variant	Pathogenic	rs28933068	GRCh37	Chromosome 4, 1807371: 1807371
47	FGFR3	NM_001163213.1(FGFR3): c.1626C> G (p.Asn542Lys)	single nucleotide variant	Pathogenic	rs28933068	GRCh38	Chromosome 4, 1805644: 1805644
48	FGFR3	NM_000142.4(FGFR3): c.746C> G (p.Ser249Cys)	single nucleotide variant	Pathogenic	rs121913483	GRCh37	Chromosome 4, 1803568: 1803568
49	FGFR3	NM_000142.4(FGFR3): c.746C> G (p.Ser249Cys)	single nucleotide variant	Pathogenic	rs121913483	GRCh38	Chromosome 4, 1801841: 1801841
50	FGFR3	NM_000142.4(FGFR3): c.749C> G (p.Pro250Arg)	single nucleotide variant	Pathogenic	rs4647924	GRCh37	Chromosome 4, 1803571: 1803571

Copy number variations for Cervical Cancer from CNVD:

⁷ (show top 50) (show all 142)

#	CNVD ID	Chromosom	Start	End	Type	Gene Symbol	CNVD Disease
1	13747	1	1	27800000	Gain	EPHB2	Cervical cancer
2	16425	1	124300000	247249719	Arm		Cervical cancer
3	30310	1	241700000	247249719	Gain		Cervical cancer
4	31746	1	30500000	163800000	Gain	AIM2	Cervical cancer
5	32175	1	34400000	39600000	Gain	CDCA8	Cervical cancer
6	47124	10	89600000	98000000	Loss	PTEN	Cervical cancer
7	48645	11	101600000	102400000	Amplification	MMP1	Cervical cancer
8	48646	11	101600000	102400000	Amplification	MMP13	Cervical cancer
9	51761	11	130300000	134452384	Loss		Cervical cancer
10	51791	11	130800000	135006516	Loss	HNT	Cervical cancer
11	51792	11	130800000	135006516	Loss	OPCML	Cervical cancer
12	55435	11	52900000	134452384	Loss		Cervical cancer
13	57095	11	63100000	130300000	Loss	INT2	Cervical cancer
14	57096	11	63100000	130300000	Loss	MEN1	Cervical cancer
15	57097	6	99389300	99393387	Loss	POUF3	Cervical cancer
16	57098	11	63100000	130300000	Loss	TRIM29	Cervical cancer
17	59362	11	74700000	85300000	Gain		Cervical cancer
18	77051	13	39500000	52200000	Loss	RB	Cervical cancer
19	81044	14	100400000	106368585	Gain	AKT1	Cervical cancer
20	97280	16	1	40700000	Loss		Cervical cancer
21	106741	17	1	11200000	Loss	TP53	Cervical cancer
22	108734	17	22200000	28800000	Loss	CCL2	Cervical cancer
23	109725	17	28500000	29700000	Amplification		Cervical cancer
24	109738	17	28800000	35400000	Amplification	ERBB2	Cervical cancer
25	111034	17	34900000	35300000	Amplification		Cervical cancer
26	111283	17	35400000	54900000	Amplification	ABCC3	Cervical cancer
27	112092	17	37856253	37884915	Amplification	ERBB2	Cervical cancer
28	112304	17	38544772	38574202	Amplification	TOP2A	Cervical cancer
29	117589	17	72900000	78774742	Gain		Cervical cancer
30	124103	19	1	30200000	Gain		Cervical cancer
31	124104	19	1	30200000	Loss		Cervical cancer
32	124177	19	1	6900000	Gain	SMARCA4	Cervical cancer
33	124219	19	1	6900000	Gain		Cervical cancer
34	124597	19	1156797	1179434	Deletion	LKB1	Cervical Cancer
35	124598	19	1156797	1179434	Deletion	LKB1	Cervical cancer
36	130163	19	47800000	57600000	Gain	LIG1	Cervical cancer
37	134165	19	9500000	14500000	Gain		Cervical cancer
38	140388	2	197100000	242951149	Loss	CASP10	Cervical cancer
39	140389	2	197100000	242951149	Loss	CFLAR	Cervical cancer
40	140390	2	197100000	242951149	Loss	PPP1R7	Cervical cancer
41	151917	20	27100000	28400000	Amplification	AHCY	Cervical cancer
42	151918	20	27100000	28400000	Amplification	ASXL1	Cervical cancer
43	151919	20	27100000	28400000	Amplification	C20orf20	Cervical cancer
44	151920	20	27100000	28400000	Amplification	E2F1	Cervical cancer
45	151921	20	27100000	28400000	Amplification	GSS	Cervical cancer
46	151922	20	27100000	28400000	Amplification	KIF3B	Cervical cancer
47	151923	20	27100000	28400000	Amplification	POFUT1	Cervical cancer
48	151924	20	27100000	28400000	Amplification	TPX2	Cervical cancer
49	153446	20	37100000	41100000	Gain	AIB1	Cervical cancer
50	153736	20	41100000	49200000	Amplification	ADNP	Cervical cancer

Sources

Expression for Cervical Cancer

Search GEO for disease gene expression data for Cervical Cancer.

Sources

Pathways for Cervical Cancer

Pathways related to Cervical Cancer according to KEGG:

³⁸

#	Name	Kegg Source Accession
1	Human papillomavirus infection	hsa05165
2	Viral carcinogenesis	hsa05203

Pathways related to Cervical Cancer according to GeneCards Suite gene sharing:

(show top 50) (show all 164)

#	Super pathways	Score	Top Affiliating Genes
1	Signaling by GPCR ⁶⁷ Show member pathways GPCR downstream signaling ⁶⁷ Signal Transduction ⁶⁷	14.31	AKT1 CCND1 CTNNB1 ERBB2 FGFR3 GNAS
2	Innate Immune System ⁶⁷ Show member pathways Immune System ⁶⁷ Neutrophil degranulation ⁶⁷	14.16	AKT1 CCND1 CTNNB1 ERBB2 FGFR3 HRAS
3	ERK Signaling ⁶⁵ Show member pathways ILK Signaling ⁶⁵ MAPK Signaling ⁶⁵ Molecular Mechanisms of Cancer ⁶⁵ Rho Family GTPases ⁶⁵	14.01	AKT1 CCND1 CTNNB1 ERBB2 FGFR3 GNAS
4	GPCR Pathway ⁶⁵ Show member pathways Breast Cancer Regulation by Stathmin1 ⁶⁵ Estrogen Pathway ⁶⁵ NFAT in Immune Response ⁶⁵ P2Y Receptor Signaling ⁶⁵ Pancreatic Adenocarcinoma ⁶⁵ Paxillin Interactions ⁶⁵ Ras Pathway ⁶⁵	13.84	AKT1 CCND1 ERBB2 FGFR3 GNAS HRAS
5	HIV Life Cycle ⁶⁷ Show member pathways 2-LTR circle formation ⁶⁷ APOBEC3G mediated resistance to HIV-1 infection ⁶⁷ Assembly Of The HIV Virion ⁶⁷ Binding and entry of HIV virion ⁶⁷ Disease ⁶⁷ Diseases of signal transduction ⁶⁷ Early Phase of HIV Life Cycle ⁶⁷ HIV Infection ⁶⁷ Host Interactions of HIV factors ⁶⁷ Infectious disease ⁶⁷ Integration of provirus ⁶⁷ Late Phase of HIV Life Cycle ⁶⁷	13.84	AKT1 CTNNB1 ERBB2 FGFR3 HRAS MTOR
6	PEDF Induced Signaling ⁶⁵ Show member pathways all-trans-Retinoic Acid Signaling in Brain ⁶⁵ Cytokine-cytokine receptor interaction ³⁸ Endothelin-1 Signaling Pathway ⁶⁵ Glucocorticoid Receptor Signaling ⁶⁵ IL-6 Pathway ⁶⁵ MIF Mediated Glucocorticoid Regulation ⁶⁵ MIF Regulation of Innate Immune Cells ⁶⁵ NFAT Signaling and Lymphocyte Interactions ⁶⁵ PGC1Alpha Pathway ⁶⁵ RAR-Gamma-RXR-Alpha Degradation ⁶⁵ STAT3 Pathway ⁶⁵	13.8	AKT1 ERBB2 FGFR3 GNAS HRAS MTOR
7	TGF-Beta Pathway ⁶⁵ Show member pathways JAK-STAT Pathway ⁶⁵ JNK Pathway ⁶⁵ MAPK Family Pathway ⁶⁵ Regulation of eIF4 and p70S6K ⁶⁵ SOCS Pathway ⁶⁵	13.69	AKT1 ERBB2 FGFR3 GNAS HRAS MTOR
8	Activation of cAMP-Dependent PKA ⁶⁵ Show member pathways Activation of PKA through GPCR ⁶⁵ cAMP Pathway ⁶⁵ PKA Signaling ⁶⁵	13.67	AKT1 CTNNB1 ERBB2 FGFR3 GNAS HRAS
9	Developmental Biology ⁶⁷ Show member pathways Axon guidance ⁶⁷	13.62	AKT1 CTNNB1 ERBB2 FGFR3 HRAS PIK3CA
10	Class I MHC mediated antigen processing and presentation ⁶⁷ Show member pathways Adaptive Immune System ⁶⁷ Antigen processing- Ubiquitination and Proteasome degradation ⁶⁷	13.58	AKT1 ERBB2 FGFR3 HRAS MTOR PIK3CA
11	Akt Signaling ⁶⁵ Show member pathways p38 Signaling ⁶⁵ Tec Kinases Signaling ⁶⁵	13.57	AKT1 CCND1 ERBB2 FGFR3 GNAS HRAS
12	Cytokine Signaling in Immune system ⁶⁷ Show member pathways Signaling by Interleukins ⁶⁷	13.5	AKT1 CCND1 ERBB2 FGFR3 HRAS PIK3CA
13	PAK Pathway ⁶⁵ Show member pathways Antioxidant Action of Vitamin-C ⁶⁵ Epithelial Adherens Junctions ⁶⁵	13.42	AKT1 CTNNB1 ERBB2 FGFR3 HRAS PTEN
14	IL-2 Pathway ⁶⁵ Show member pathways ErbB Family Pathway ⁶⁵ ErbB2-ErbB3 Heterodimers ⁶⁵ ErbB4 Pathway ⁶⁵ Growth Hormone Signaling ⁶⁵ HMGB1 Pathway ⁶⁵ IL-4 Pathway ⁶⁵ LPS Stimulated MAPK Signaling ⁶⁵ PACAP Signaling ⁶⁵ PI3K Signaling in B-Lymphocyte ⁶⁵ Prolactin Signaling ⁶⁵ Thrombopoietin Pathway ⁶⁵ TREM1 Pathway ⁶⁵ UVC-Induced MAPK Signaling ⁶⁵	13.38	AKT1 CCND1 ERBB2 GNAS HRAS MTOR
15	Phospholipase-C Pathway ⁶⁵ Show member pathways PTEN Pathway ⁶⁵	13.21	AKT1 FGFR3 GNAS HRAS MTOR PTEN
16	p70S6K Signaling ⁶⁵ Show member pathways mTOR Pathway ⁶⁵ Renin-Angiotensin Pathway ⁶⁵	13.17	AKT1 FGFR3 GNAS HRAS MTOR STAT3
17	fMLP Pathway ⁶⁵ Show member pathways Alpha-Adrenergic Signaling ⁶⁵ CCR3 Pathway in Eosinophils ⁶⁵ CXCR4 Pathway ⁶⁵ Huntington's Disease Pathway ⁶⁵ Internalin Pathway ⁶⁵ Signal transduction Activation of PKC via G-Protein coupled receptor ²³ VEGF and S-1P Signaling ⁶⁵	13.13	AKT1 CTNNB1 GNAS HRAS STAT3 TP53
18	PI3K-Akt signaling pathway ³⁸ Show member pathways Human papillomavirus infection ³⁸	13.11	AKT1 CCND1 CTNNB1 ERBB2 FGFR3 GNAS
19	TNFR1 Pathway ⁶⁵ Show member pathways Apoptosis and survival TNFR1 signaling pathway ²³ Apoptosis through Death Receptors ⁶⁵ Apoptotic Pathways Triggered By HIV1 ⁶⁵ DR3 Signaling ⁶⁵ Fas Signaling ⁶⁵ GITR Pathway ⁶⁵ HIV-1 Nef- Negative effector of Fas and TNF-alpha ¹ Stimulation of the cell death response by PAK-2p34 ⁶⁷ TNF alpha Signaling Pathway ¹ TNF related weak inducer of apoptosis (TWEAK) Signaling Pathway ¹ TNF Signaling ⁶⁵ TRAIL Pathway ⁶⁵ TWEAK Pathway ⁶⁵	13.1	AKT1 CTNNB1 HRAS MTOR PIK3CA PTEN
20	Human cytomegalovirus infection ³⁸ Show member pathways Human immunodeficiency virus 1 infection ³⁸ Kaposi sarcoma-associated herpesvirus infection ³⁸	13.09	AKT1 CCND1 CTNNB1 GNAS HRAS MTOR
21	Regulation of lipid metabolism Insulin signaling-generic cascades ²³ Show member pathways acetyl-CoA biosynthesis from citrate ¹ Butyrate-induced histone acetylation ¹ Cell adhesion PLAU signaling ²³ Class IB PI3K non-lipid kinase events ¹ Development CNTF receptor signaling ²³ Development Growth hormone signaling via PI3K/AKT and MAPK cascades ²³ ErbB2/ErbB3 signaling events ¹ Glucose Homeostasis ¹ Insulin signaling pathway ³⁸ IRS activation ⁶⁷ Signal attenuation ⁶⁷ Transcription Receptor-mediated HIF regulation ²³ Translation Regulation of EIF2 activity ²³ Translation Regulation of EIF4F activity ²³ Translation Insulin regulation of translation ²³	13.07	AKT1 ERBB2 HRAS MTOR PIK3CA PTEN
22	Focal Adhesion ¹ ³⁸ Show member pathways HGF Pathway ⁶⁵ Integrin-mediated Cell Adhesion ¹	13.07	AKT1 CCND1 CTNNB1 ERBB2 HRAS PIK3CA
23	NFAT and Cardiac Hypertrophy ⁶⁵ Show member pathways IGF1R Signaling ⁶⁵ Signaling Involved in Cardiac Hypertrophy ⁶⁵	13.06	AKT1 ERBB2 FGFR3 GNAS HRAS MTOR
24	CCR5 Pathway in Macrophages ⁶⁵ Show member pathways Androgen Signaling ⁶⁵ Chemokine Signaling ⁶⁵ Chemokine signaling pathway ³⁸	13.02	AKT1 CCND1 GNAS HRAS PIK3CA STAT3
25	Endometrial cancer ³⁸ Show member pathways Acute myeloid leukemia ³⁸ Binding of TCF/LEF-CTNNB1 to target gene promoters ⁶⁷ Chronic myeloid leukemia ³⁸ Colorectal cancer ³⁸ Pancreatic cancer ³⁸ Prostate cancer ³⁸ Signal transduction PTEN pathway ²³ Thyroid cancer ³⁸	12.98	AKT1 CCND1 CTNNB1 ERBB2 HRAS MTOR
26	Common Cytokine Receptor Gamma-Chain Family Signaling Pathways ⁶⁶ Show member pathways Adipokines and Insulin Signaling Pathways ⁶⁶ Development Thrombopoietin-regulated cell processes ²³ IL-15 Signaling Pathways ⁶⁶ IL-2 Signaling Pathways ⁶⁶ IL-21 Signaling Pathways ⁶⁶ IL-4 Signaling Pathways ⁶⁶ IL-7 Signaling Pathways ⁶⁶ IL-9 Pathway ⁶⁵ IL-9 Signaling Pathways ⁶⁶ Immune response IL-9 signaling pathway ²³	12.96	AKT1 CCND1 HRAS MTOR PIK3CA PTEN
27	Downstream signaling events of B Cell Receptor (BCR) ⁶⁷ Show member pathways Activation of RAS in B cells ⁶⁷ Signaling by the B Cell Receptor (BCR) ⁶⁷	12.93	AKT1 ERBB2 FGFR3 HRAS MTOR PIK3CA
28	Beta-Adrenergic Signaling ⁶⁵ Show member pathways CDK5 Pathway ⁶⁵ Erythropoietin Pathway ⁶⁵ Insulin Receptor Pathway ⁶⁵	12.92	AKT1 CTNNB1 GNAS HRAS MTOR
29	Development HGF signaling pathway ²³ Show member pathways Apoptosis and survival Anti-apoptotic action of membrane-bound ESR1 ²³ Apoptosis and survival NGF signaling pathway ²³ Apoptosis and survival Role of CDK5 in neuronal death and survival ²³ Development Neurotrophin family signaling ²³ MET activates PTPN11 ⁶⁷ MET activates STAT3 ⁶⁷ Neurotrophin signaling pathway ³⁸ Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met) ¹ Signaling of Hepatocyte Growth Factor Receptor ¹	12.91	AKT1 CTNNB1 ERBB2 HRAS MTOR PIK3CA
30	Ras signaling pathway ³⁸ Show member pathways Rap1 signaling pathway ³⁸	12.89	AKT1 CTNNB1 FGFR3 GNAS HRAS PIK3CA
31	MAPK signaling pathway ¹ ³⁸	12.88	AKT1 ERBB2 FGFR3 HRAS TP53
32	Development Endothelin-1/EDNRA signaling ²³ Show member pathways Cytoskeleton remodeling FAK signaling ²³ Development Endothelin-1/EDNRA transactivation of EGFR ²³ GnRH signaling pathway ³⁸ Inflammatory mediator regulation of TRP channels ³⁸	12.87	AKT1 CCND1 CTNNB1 GNAS HRAS MTOR
33	Gastric cancer ³⁸ Show member pathways Breast cancer ³⁸ Hepatocellular carcinoma ³⁸	12.84	AKT1 CCND1 CTNNB1 ERBB2 HRAS MTOR
34	ErbB signaling pathway ¹ ³⁸ Show member pathways EGFR Inhibitor Pathway, Pharmacodynamics ⁶² EGFR tyrosine kinase inhibitor resistance ³⁸ Renal cell carcinoma ³⁸ TCA Cycle Nutrient Utilization and Invasiveness of Ovarian Cancer ¹	12.8	AKT1 CCND1 ERBB2 HRAS MTOR PIK3CA
35	Glioma ³⁸ Show member pathways Endocrine resistance ³⁸ Melanoma ³⁸ Non-small cell lung cancer ³⁸ Signaling Pathways in Glioblastoma ¹	12.79	AKT1 CCND1 ERBB2 FGFR3 GNAS HRAS
36	Immune response IL-23 signaling pathway ²³ Show member pathways Angiopoietin receptor Tie2-mediated signaling ¹ Angiopoietin-TIE2 Signaling ⁶⁵ Development Angiopoietin - Tie2 signaling ²³ Development PDGF signaling via STATs and NF-kB ²³ IL23-mediated signaling events ¹ Immune response IL-10 signaling pathway ²³ Rac1/Pak1/p38/MMP-2 pathway ¹	12.77	AKT1 CTNNB1 ERBB2 HRAS PIK3CA STAT3
37	Notch signaling pathway (KEGG) ¹ Show member pathways Notch Signaling ⁶⁵ Notch signaling pathway ³⁸ Notch Signaling Pathway ¹ Notch Signaling Pathway ¹ Notch Signaling Pathways ⁶⁶	12.73	AKT1 CCND1 CTNNB1 MTOR STAT3
38	mTOR signaling pathway (KEGG) ³⁸ Show member pathways mTOR Signaling Pathway ⁶⁶	12.72	AKT1 ERBB2 FGFR3 HRAS MTOR PIK3CA
39	Development Dopamine D2 receptor transactivation of EGFR ²³ Show member pathways Apoptosis and survival BAD phosphorylation ²³ BAD Phosphorylation ⁶⁵ Chemotaxis CXCR4 signaling pathway ²³ Development Alpha-2 adrenergic receptor activation of ERK ²³	12.71	AKT1 GNAS HRAS PIK3CA STAT3
40	Prolactin Signaling Pathway ¹ ³⁸ Show member pathways Development Prolactin receptor signaling ²³ Leptin signaling pathway ¹	12.7	AKT1 CCND1 ERBB2 HRAS MTOR PIK3CA
41	Angiopoietin Like Protein 8 Regulatory Pathway ¹ Show member pathways Insulin Signaling ¹ Liver X Receptor Pathway ¹	12.67	AKT1 HRAS MTOR PIK3CA PTEN
42	Development EGFR signaling pathway ²³ Show member pathways Development ERBB-family signaling ²³ EGF Pathway ⁶⁵ EGFR Signaling Pathway ⁶⁸ ErbB receptor signaling network ¹	12.66	AKT1 CCND1 CTNNB1 ERBB2 HRAS MTOR
43	MET promotes cell motility ⁶⁷ Show member pathways Alpha 6 Beta 4 signaling pathway ¹ Laminin interactions ⁶⁷ MET activates PTK2 signaling ⁶⁷ MET activates RAP1 and RAC1 ⁶⁷ MET activates RAS signaling ⁶⁷ MET interacts with TNS proteins ⁶⁷ MET Receptor Activation ⁶⁷ MET receptor recycling ⁶⁷ Non-integrin membrane-ECM interactions ⁶⁷ Signaling by MET ⁶⁷ Syndecan interactions ⁶⁷	12.63	AKT1 HRAS MTOR PIK3CA STAT3
44	Apoptosis Pathway ⁷³ Show member pathways Akt Pathway ⁷³ NF-kappaB Pathway ⁷³	12.63	AKT1 CTNNB1 ERBB2 FGFR3 HRAS MTOR
45	AMP-activated Protein Kinase (AMPK) Signaling ¹ Show member pathways AMPK signaling pathway ³⁸ AMPK Signaling Pathway ⁶⁸	12.62	AKT1 CCND1 HRAS MTOR PIK3CA TP53
46	JAK-STAT signaling pathway (KEGG) ⁶⁶ Show member pathways Interleukin-19, 20, 22, 24 ⁶⁷ JAK-STAT signaling pathway ³⁸	12.59	AKT1 CCND1 HRAS MTOR PIK3CA STAT3
47	WNT Signaling ⁶⁵	12.58	AKT1 CCND1 CTNNB1 GNAS TP53
48	G-protein signaling RAC1 in cellular process ²³ Show member pathways CDC42 signaling events ¹ Cytoskeleton remodeling CDC42 in cellular processes ²³ RAC1 signaling pathway ¹	12.57	CTNNB1 ERBB2 FGFR3 HRAS MTOR PIK3CA
49	Human T-cell leukemia virus 1 infection ³⁸	12.57	AKT1 CCND1 CTNNB1 HRAS PIK3CA SMAD4
50	Development IGF-1 receptor signaling ²³ Show member pathways IL-4 Signaling Pathway ¹ Immune response IL-4 signaling pathway ²³ Signal transduction AKT signaling ²³	12.57	AKT1 CCND1 HRAS MTOR PIK3CA PTEN

Sources

GO Terms for Cervical Cancer

Cellular components related to Cervical Cancer according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	cytosol	GO:0005829	9.73	AKT1 CCND1 CTNNB1 ERBB2 GNAS MTOR
2	cytoplasm	GO:0005737	9.5	AKT1 CCND1 CTNNB1 ERBB2 FGFR3 GNAS
3	nucleus	GO:0005634	10	AKT1 CCND1 CTNNB1 ERBB2 FGFR3 GNAS

Biological processes related to Cervical Cancer according to GeneCards Suite gene sharing:

(show all 50)

#	Name	GO ID	Score	Top Affiliating Genes
1	negative regulation of gene expression	GO:0010629	9.97	AKT1 CTNNB1 HRAS MIR21 MIR214
2	positive regulation of cell proliferation	GO:0008284	9.97	AKT1 CCND1 CTNNB1 FGFR3 HRAS MIR21
3	aging	GO:0007568	9.96	AKT1 NFE2L2 PTEN STAT3
4	protein autophosphorylation	GO:0046777	9.96	AKT1 ERBB2 FGFR3 MTOR
5	positive regulation of MAPK cascade	GO:0043410	9.92	CTNNB1 ERBB2 FGFR3 HRAS
6	positive regulation of protein kinase B signaling	GO:0051897	9.89	ERBB2 FGFR3 MIR21 MTOR PIK3CA
7	response to estradiol	GO:0032355	9.88	CCND1 CTNNB1 PTEN STAT3
8	negative regulation of apoptotic process	GO:0043066	9.88	AKT1 CTNNB1 MIR21 PTEN STAT3 TP53
9	negative regulation of ERK1 and ERK2 cascade	GO:0070373	9.87	MIR21 PTEN SMAD4
10	negative regulation of cell death	GO:0060548	9.86	NFE2L2 SMAD4 STAT3
11	positive regulation of ERK1 and ERK2 cascade	GO:0070374	9.86	FGFR3 HRAS MIR21 PTEN
12	negative regulation of cell proliferation	GO:0008285	9.86	CTNNB1 HRAS MIR21 MIR214 PTEN SMAD4
13	positive regulation of osteoblast differentiation	GO:0045669	9.85	CTNNB1 GNAS MIR21
14	cellular response to growth factor stimulus	GO:0071363	9.85	AKT1 CTNNB1 ERBB2
15	response to organic substance	GO:0010033	9.85	AKT1 CCND1 PTEN STAT3
16	negative regulation of neuron death	GO:1901215	9.84	AKT1 CTNNB1 STAT3
17	protein kinase B signaling	GO:0043491	9.8	AKT1 PIK3CA PTEN
18	positive regulation of protein phosphorylation	GO:0001934	9.8	AKT1 CCND1 ERBB2 HRAS MIR21 MTOR
19	activation of protein kinase B activity	GO:0032148	9.78	AKT1 MIR21 MTOR
20	phosphatidylinositol 3-kinase signaling	GO:0014065	9.77	AKT1 ERBB2 PIK3CA
21	cell aging	GO:0007569	9.76	HRAS MTOR TP53
22	positive regulation of epithelial to mesenchymal transition	GO:0010718	9.73	CTNNB1 MIR21 MTOR SMAD4
23	negative regulation of vascular associated smooth muscle cell migration	GO:1904753	9.71	MIR21 MIR214 NFE2L2
24	regulation of mitochondrial membrane permeability	GO:0046902	9.7	STAT3 TP53
25	regulation of protein kinase B signaling	GO:0051896	9.7	MIR21 MTOR
26	response to leptin	GO:0044321	9.7	CCND1 STAT3
27	cellular response to leptin stimulus	GO:0044320	9.7	PTEN STAT3
28	regulation of myelination	GO:0031641	9.7	AKT1 CTNNB1 MTOR
29	positive regulation of metalloendopeptidase activity	GO:1904685	9.69	MIR21 STAT3
30	negative regulation of macroautophagy	GO:0016242	9.69	AKT1 MTOR PIK3CA
31	mitotic G1 DNA damage checkpoint	GO:0031571	9.68	CCND1 TP53
32	endothelial tube morphogenesis	GO:0061154	9.68	CTNNB1 MIR21
33	regulation of glycogen biosynthetic process	GO:0005979	9.67	AKT1 MTOR
34	hair follicle placode formation	GO:0060789	9.65	CTNNB1 GNAS
35	anoikis	GO:0043276	9.65	AKT1 MTOR PIK3CA
36	cellular response to decreased oxygen levels	GO:0036294	9.63	AKT1 PTEN
37	negative regulation of cell size	GO:0045792	9.63	AKT1 MTOR PTEN
38	cellular response to hypoxia	GO:0071456	9.63	AKT1 MIR214 MTOR NFE2L2 PTEN TP53
39	response to UV-A	GO:0070141	9.61	AKT1 CCND1
40	cell proliferation	GO:0008283	9.56	AKT1 CTNNB1 ERBB2 HRAS PTEN SMAD4
41	positive regulation of transcription by RNA polymerase III	GO:0045945	9.4	MTOR
42	positive regulation of gene expression	GO:0010628	9.32	AKT1 CTNNB1 ERBB2 HRAS MIR21 MTOR
43	positive regulation of transcription by RNA polymerase II	GO:0045944	10.23	AKT1 CTNNB1 HRAS NFE2L2 SMAD4 STAT3
44	phosphorylation	GO:0016310	10.14	AKT1 ERBB2 FGFR3 MTOR PIK3CA STAT3
45	protein phosphorylation	GO:0006468	10.13	AKT1 CCND1 ERBB2 FGFR3 MTOR PIK3CA
46	nervous system development	GO:0007399	10.11	AKT1 CTNNB1 ERBB2 PTEN STAT3
47	positive regulation of transcription, DNA-templated	GO:0045893	10.11	AKT1 CTNNB1 NFE2L2 SMAD4 STAT3 TP53
48	positive regulation of apoptotic process	GO:0043065	10.04	AKT1 CTNNB1 MIR21 PTEN TP53
49	response to drug	GO:0042493	10.03	CCND1 CTNNB1 GNAS PTEN STAT3
50	cytokine-mediated signaling pathway	GO:0019221	10	AKT1 CCND1 PIK3CA STAT3 TP53

Molecular functions related to Cervical Cancer according to GeneCards Suite gene sharing:

(show all 11)

#	Name	GO ID	Score	Top Affiliating Genes
1	kinase activity	GO:0016301	9.88	AKT1 CCND1 ERBB2 FGFR3 MTOR PIK3CA
2	transcription regulatory region DNA binding	GO:0044212	9.78	NFE2L2 SMAD4 STAT3 TP53
3	identical protein binding	GO:0042802	9.76	AKT1 ERBB2 FGFR3 MTOR PTEN SMAD4
4	nucleotide binding	GO:0000166	9.73	ERBB2 FGFR3 HRAS MTOR
5	enzyme binding	GO:0019899	9.72	AKT1 CCND1 CTNNB1 PTEN TP53
6	transcription factor binding	GO:0008134	9.65	CCND1 CTNNB1 NFE2L2 STAT3 TP53
7	RNA polymerase II transcription factor binding	GO:0001085	9.54	CTNNB1 SMAD4 TP53
8	I-SMAD binding	GO:0070411	9.49	CTNNB1 SMAD4
9	protein phosphatase binding	GO:0019903	9.26	CTNNB1 ERBB2 STAT3 TP53
10	protein kinase binding	GO:0019901	9.17	AKT1 CCND1 CTNNB1 MTOR PTEN STAT3
11	phosphatidylinositol-4,5-bisphosphate 3-kinase activity	GO:0046934	9.16	PIK3CA

Sources

Sources for Cervical Cancer

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ EFO

¹⁸ ExPASy

¹⁹ FDA Approved Drugs

²⁰ FMA

²¹ GeneAnalytics

²² GeneCards

²³ GeneGo (Thomson Reuters)

²⁴ GeneHancer via GeneCards

²⁵ GeneReviews

²⁶ Genetics Home Reference

²⁷ GenomeRNAi

²⁸ GEO DataSets

²⁹ GO

³⁰ GTR

³¹ HGMD

³² HMDB

³³ HPO

³⁴ ICD10

³⁵ ICD10 via Orphanet

³⁶ ICD9CM

³⁷ IUPHAR

³⁸ KEGG

³⁹ LifeMap

⁴⁰ LncRNADisease

⁴¹ LOVD

⁴² MalaCards

⁴³ MedGen

⁴⁴ MedlinePlus

⁴⁵ MeSH

⁴⁶ MESH via Orphanet

⁴⁷ MGI

⁴⁸ miR2Disease

⁴⁹ NCBI Bookshelf

⁵⁰ NCI

⁵¹ NCIt

⁵² NDF-RT

⁵³ NIH Clinical Center

⁵⁴ NIH Rare Diseases

⁵⁵ NINDS

⁵⁶ Novoseek

⁵⁷ Novus Biologicals

⁵⁸ OMIM

⁵⁹ OMIM via Orphanet

⁶⁰ Orphanet

⁶¹ PathCards

⁶² PharmGKB

⁶³ PubMed

⁶⁴ PubMed Health

⁶⁵ QIAGEN

⁶⁶ R&D Systems

⁶⁷ Reactome

⁶⁸ Sino Biological

⁶⁹ SNOMED-CT

⁷⁰ SNOMED-CT via HPO

⁷¹ SNOMED-CT via Orphanet

⁷² TGDB

⁷³ Tocris

⁷⁴ UMLS

⁷⁵ UMLS via Orphanet

⁷⁶ UniProtKB/Swiss-Prot

⁷⁷ Wikipedia

Cervical Cancer (CERCA)

Aliases & Classifications for Cervical Cancer

MalaCards integrated aliases for Cervical Cancer:

Characteristics:

HPO:

Classifications:

External Ids:

Summaries for Cervical Cancer

Related Diseases for Cervical Cancer

Diseases related to Cervical Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

Comorbidity relations with Cervical Cancer via Phenotypic Disease Network (PDN):

Graphical network of the top 20 diseases related to Cervical Cancer:

Symptoms & Phenotypes for Cervical Cancer

Human phenotypes related to Cervical Cancer:

Clinical features from OMIM:

UMLS symptoms related to Cervical Cancer:

GenomeRNAi Phenotypes related to Cervical Cancer according to GeneCards Suite gene sharing:

MGI Mouse Phenotypes related to Cervical Cancer:

Drugs & Therapeutics for Cervical Cancer

PubMedHealth treatment related to Cervical Cancer: 64

FDA approved drugs:

Drugs for Cervical Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

Interventional clinical trials:

Cochrane evidence based reviews: uterine cervical neoplasms

Genetic Tests for Cervical Cancer

Anatomical Context for Cervical Cancer

MalaCards organs/tissues related to Cervical Cancer:

The Foundational Model of Anatomy Ontology organs/tissues related to Cervical Cancer:

Publications for Cervical Cancer

Articles related to Cervical Cancer:

Genes for Cervical Cancer

Genes related to Cervical Cancer (14 elite genes):

Variations for Cervical Cancer

UniProtKB/Swiss-Prot genetic disease variations for Cervical Cancer:

ClinVar genetic disease variations for Cervical Cancer:

Copy number variations for Cervical Cancer from CNVD:

Expression for Cervical Cancer

Pathways for Cervical Cancer

Pathways related to Cervical Cancer according to KEGG:

Pathways related to Cervical Cancer according to GeneCards Suite gene sharing:

GO Terms for Cervical Cancer

Cellular components related to Cervical Cancer according to GeneCards Suite gene sharing:

Biological processes related to Cervical Cancer according to GeneCards Suite gene sharing:

Molecular functions related to Cervical Cancer according to GeneCards Suite gene sharing:

Sources for Cervical Cancer

PubMedHealth treatment related to Cervical Cancer: ⁶⁴